Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder

Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder

Form: Lyophilized Powder (Reconstituted for IV infusion)

Strength: 500 units, 1000 units, and 2500 units

Reference Brands: FEIBA(US)

Category: Blood Disorder

Anti-Inhibitor Coagulant Complex (AICC), such as FEIBA, is approved in the US by the FDA and in the EU via EMA for managing bleeding in hemophilia patients with inhibitors. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews comprehensive clinical and manufacturing information, while the EMA ensures compliance with regional safety and quality requirements. For guidance on dossier preparation, regulatory strategies, and market access, visit PharmaTradz. Ensuring regional compliance is essential for the safe, effective, and timely approval of AICC products worldwide, supporting optimal hemophilia patient care.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Prothrombin Complex Concentrate (PCC) injection

Strength: 250 IU to 300 IU

Form: Injection

Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)

View Details Get Enquiry
Mesna Injection

Strength: 100 mg/mL

Form: Injection

Reference Brands: Mesnex(US)

View Details Get Enquiry
Leucovorin tablets/Capsule

Strength: 15 mg, 50 mg

Form: Tablet/Capsules

Reference Brands: Folvite(US & EU)

View Details Get Enquiry
Pegfilgrastim injection

Strength: 6 mg per single-use syringe

Form: Injection

Reference Brands: Neulasta, Pelgraz(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.